Triplet Therapeutics
Peter joined Triplet Therapeutics, Inc. in 2018 as Head of Translational Sciences. He has worked in drug development for over 13 years, focusing on translational biology and biomarker strategies from early development into the clinic. His broad experience across multiple rare disease areas includes neuromuscular, pulmonary, neuroscience, blood and liver diseases. Most recently, Peter was Director of Translational Science at Intellia Therapeutics where he worked across therapeutic areas to investigate appropriate biomarker strategies for target engagement, disease mechanism and safety readouts. Previously, he worked at Proteostasis, RaNA Therapeutics and Pfizer. Peter received his PhD in Biochemistry from the University of Western Ontario, Canada.
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.